{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T02:22:53Z","timestamp":1774578173619,"version":"3.50.1"},"reference-count":52,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The public subsidy in Australia of bortezomib (Velcade) for untreated non\u2010transplant multiple myeloma patients was based on the VISTA trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To ascertain the health outcomes of bortezomib in \u2018real world\u2019 transplant\u2010ineligible elderly patients, compared to trial data.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patient and treatment data were extracted from an oncology information system, laboratory information system and medical chart audits for three Queensland public hospitals.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We identified 74 patients; the median age was 75\u2009years. Our cohort comprised 47% patients who were International Staging System stage III, 45% at stage II and 8% at stage I. Patients who had comorbidities, such as cardiac disease (41%), pulmonary disease (14%), diabetes (22%), peripheral neuropathy (14%) and other comorbidities (41%) at baseline were included. The common regimens prescribed were VMP, CVD and VD, and most patients (<jats:italic>n<\/jats:italic> =\u200973) received bortezomib on a once\u2010weekly or twice\u2010a\u2010week basis. The overall response rate was 81%. Half (53%) of the patients did not complete their planned therapy due to toxicity (30%), suboptimal response or disease progression (15%), or death on treatment (8%). Overall survival was 40.7 months and progression free survival was 17.7 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our patients were older, had worse disease characteristics and more comorbidities than patients in the VISTA trial. While response rates were similar, survival outcomes appeared worse. Bortezomib\u2010based treatment in the real world setting still carries a high risk of toxicity in the elderly population.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.14886","type":"journal-article","created":{"date-parts":[[2020,5,5]],"date-time":"2020-05-05T15:25:51Z","timestamp":1588692351000},"page":"1059-1066","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bortezomib use and outcomes for the treatment of multiple myeloma"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4639-1428","authenticated-orcid":false,"given":"Crystal","family":"Loke","sequence":"first","affiliation":[{"name":"School of Pharmacy The University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Mollee","sequence":"additional","affiliation":[{"name":"Department of Cancer Services Princess Alexandra Hospital  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"McPherson","sequence":"additional","affiliation":[{"name":"Department of Cancer Services Princess Alexandra Hospital  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Euan","family":"Walpole","sequence":"additional","affiliation":[{"name":"Department of Cancer Services Princess Alexandra Hospital  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mimi","family":"Yue","sequence":"additional","affiliation":[{"name":"Department of Cancer Services Princess Alexandra Hospital  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Mutsando","sequence":"additional","affiliation":[{"name":"Toowoomba Hospital Darling Downs Hospital and Health Services  Toowoomba Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Wong","sequence":"additional","affiliation":[{"name":"Toowoomba Hospital Darling Downs Hospital and Health Services  Toowoomba Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Weston","sequence":"additional","affiliation":[{"name":"Regional Cancer Care, Cancer Care Services Sunshine Coast University Hospital  Sunshine Coast Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Regional Cancer Care, Cancer Care Services Sunshine Coast University Hospital  Sunshine Coast Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5226-5663","authenticated-orcid":false,"given":"Samantha","family":"Hollingworth","sequence":"additional","affiliation":[{"name":"School of Pharmacy The University of Queensland  Brisbane Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9,14]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"e_1_2_7_3_1","volume-title":"Australian Cancer Incidence and Mortality (ACIM) Books: Multiple Myeloma","author":"Australian Institute of Health and Welfare (AIHW)","year":"2017"},{"key":"e_1_2_7_4_1","volume-title":"Cancer in Australia: An Overview 2014","author":"Australian Institute of Health and Welfare (AIHW)","year":"2014"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728210802676278"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.47"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.12.3832"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leusup.2013.5"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.055"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.847935"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.4.5.639"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801479"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6180"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.0638"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.0023"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt297"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23810"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.12688"},{"key":"e_1_2_7_20_1","volume-title":"Pharmaceutical Benefits Schedule Item Reports. Australian Government","author":"Medicare Australia Statistics","year":"2016"},{"key":"e_1_2_7_21_1","unstructured":"AAPC. ICD\u201010 Code for Multiple myeloma C90.0;2018[cited 2018 June 25]. Available from URL:https:\/\/coder.aapc.com\/icd-10-codes\/C90.0"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-016-0250-z"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21979"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.11.710"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.8216"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-294983"},{"key":"#cr-split#-e_1_2_7_29_1.1","unstructured":"Reserve Bank of Australia. Exchange Rates - Monthly - January 2010 to latest complete month of current year. Sydney: Reserve Bank of Australia;2018[updated 2018 Jan 31"},{"key":"#cr-split#-e_1_2_7_29_1.2","unstructured":"cited 2018 Jan 31]. Available from URL:http:\/\/www.rba.gov.au\/statistics\/historical-data.html"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603498"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.099341"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0093"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-081018"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-358812"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2901-x"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2012.1018"},{"key":"e_1_2_7_37_1","first-page":"587","article-title":"Long\u2010term outcomes of different bortezomib\u2010based regimens in Chinese myeloma patients","volume":"9","author":"Wang H","year":"2016","journal-title":"Onco Targets Ther"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000381297"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12448"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12685"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.14155"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01533.x"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8027.2008.00192.x"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.483303"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2012.01788.x"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-12-615187"},{"key":"e_1_2_7_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2011.34"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.162693"},{"key":"e_1_2_7_49_1","first-page":"11","article-title":"Comparison of the Freiburg and Charlson comorbidity indices in predicting overall survival in elderly patients with newly diagnosed multiple myeloma","volume":"2014","author":"Kim SM","year":"2014","journal-title":"Biomed Res Int"},{"key":"e_1_2_7_50_1","unstructured":"Department of Health. Bortezomib powder for injection 3.5 mg 1 mg Velcade\u00ae. Canberra: Australian Government;2009."},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12571"},{"key":"e_1_2_7_52_1","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2147\/CEOR.S104195","article-title":"Cost\u2010effectiveness of bortezomib for multiple myeloma: a systematic review","volume":"8","author":"Chen W","year":"2016","journal-title":"Clinicoecon Outcomes Res"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.14886","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.14886","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/imj.14886","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.14886","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T07:51:03Z","timestamp":1693900263000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.14886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":52,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1111\/imj.14886"],"URL":"https:\/\/doi.org\/10.1111\/imj.14886","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"2019-06-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-05-01","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}